2022 Cell Biology Drug Development 
KIF1A
MARCH 2, 2024
Wendy Chung discusses advances from the Simons Foundation Powering Autism Research for Knowledge (SPARK) Project, which enrolled 275,000 participants with and without autism, between 2016 and 2022. The Jackson Laboratory is offering a short MiniCourse on modeling rare diseases for preclinical drug development.
Drug Target Review
JULY 13, 2023
The company developed methods to identify disease-driving condensates, model them, and create systems for effective drug discovery targeting these condensates. The aim is to establish condensate biology as a fundamental branch of cell biology – “cell biology 2.0”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
SEPTEMBER 19, 2023
In addition, these models at the current state are better for short term tests, over a week or two and cannot be used for acquiring data from long term drug exposures. Miniature organs as test beds for new drugs Organoids are miniature human organs with clusters of cells derived from stem cells and mimic specific tissues.
The Pharma Data
FEBRUARY 24, 2022
Their findings are published online in Nature Cell Biology. “We are amazed by the efficiency of small-molecule PROTAC in simultaneously targeting EZH2 and cMyc in cancer cells.” Nat Cell Biol, 2022. MS177 targets both EZH2 and cMyc and thus inhibit cancer growth. ” Wang J, Yu X, Gong W et al.
Alta Sciences
JANUARY 31, 2025
As experts in early-phase drug development , from discovery through Phase II clinical research , we at Altasciences can share with STC members our accumulated knowledge and experience, and provide mentorship for future toxicologists. Their passion and curiosity to expand the boundaries of toxicology research illuminated the room.
DrugBank
JUNE 27, 2023
The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care. Nucleic Acids Res.
New Drug Approvals
JANUARY 9, 2024
As such, it has been proposed that inhibiting CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle at least in most cell types (M alumbres et al.,
Expert insights. Personalized for you.
119 
Let's personalize your content